Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CG Oncology, Inc. (CGON)

CG Oncology Q3 net loss widens to $56.9 million; cash totals $984.5 million

Negative Impact 3 of 5 earnings

CG Oncology reported a third-quarter 2026 net loss of $56.9 million, or $(0.64) per share, up from $43.8 million, or $(0.57) per share, a year earlier. Total revenue was $1.6 million, down from $1.7 million, while research and development expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities were $984.5 million at September 30, 2026, which the company expects will fund operations through 2029.

Key points

  • Net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, versus $43.8 million, or $(0.57) per share, a year earlier
  • Total revenue of $1.6 million, compared with $1.7 million in the prior-year quarter
  • Research and development expenses of $39.2 million, up from $27.9 million, mainly due to higher clinical trial costs and headcount-related compensation
  • PIVOT-006 Phase 3 topline data expected November 2026; BLA completion for BCG-unresponsive NMIBC expected in Q4 2026

The filing

CompanyCG Oncology, Inc. (CGON)
Form8-K, current report
Filed with the SECNov 6, 2026, 8:30 AM ET
Accession number0001991792-26-000011

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:05 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.